Quarterly Result3 April 2026 at 08:06 am
Metropolis Healthcare Q4FY26: Revenue Grew by ~23% Y-o-Y, Fueled by TruHealth Wellness and Specialized Testing Segments
AI Summary
Metropolis Healthcare Ltd. has provided a business update for Q4FY26, highlighting a ~23% Y-o-Y growth in consolidated revenues. This growth was primarily driven by the TruHealth wellness segment and specialized testing segment. The B2B and B2C channels also showed robust growth. Acquisitions from the previous year are progressing well, with integration efforts now translating into positive outcomes. The MHL Organic segment saw a ~14.5% Y-o-Y growth in revenue, and EBITDA margins improved due to operating leverage and efficiency gains. The financial results are subject to audit.
Key Highlights
- Revenue grew by ~23% on a Y-o-Y basis including revenues from Core Diagnostics, Scientific Pathology, Dr. Ahuja’s Pathology & Imaging Center, and Dr. RS Patil’s Ambika Pathology Laboratory.
- B2C revenue grew by ~19% and B2B revenue by ~30% on Y-o-Y basis, driven by strong specialty growth and a higher B2B contribution in Core Diagnostics.
- TruHealth Wellness and Specialty segments recorded growth of ~25% and ~29%, respectively on Y-o-Y basis in Q4 FY26.
- Acquisitions completed last year are progressing well, with integration efforts and synergy benefits now translating into positive outcomes.
- Revenue grew by ~14.5% Y-o-Y for MHL Organic, largely on account of increased patient and test volume, and product mix.